S-1: CERO Therapeutics Registers Shares; Faces OTCQB Trading

CERO Therapeutics Holdings, Inc. filed an S-1 registration statement for the resale of up to 729.6 million common shares by Keystone Capital Partners, LLC, following its delisting from Nasdaq to OTCQB.

Summary

• A registration statement was filed for the potential resale of up to 729,596,950 shares of common stock by Keystone Capital Partners, LLC, which were or may be issued under a Common Stock Purchase Agreement.
• The company will not receive proceeds from Keystone's resale of these shares, but may receive up to $25 million in aggregate gross proceeds from direct sales to Keystone under the Equity Line of Credit (ELOC).
• The company was delisted from Nasdaq to OTCQB as of October 31, 2025, due to non-compliance with listing standards, including stockholders' equity and bid price requirements.
• A net loss of $15.4 million was reported for the nine months ended September 30, 2025, an increase from $9.0 million for the same period in 2024.
• The accumulated deficit reached $86.3 million as of September 30, 2025, with cash and cash equivalents of $1.9 million.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• CER-1236, the lead product candidate, received FDA Orphan Drug Designation in July 2025 and Fast Track Designation in September 2025 for acute myeloid leukemia (AML).
• A Phase 1 clinical trial for CER-1236 in AML was initiated in May 2025, with four patients dosed and no dose-limiting toxicities observed in the first three.
• A second Investigational New Drug (IND) application for CER-T cell therapy in non-small cell lung cancer (NSCLC) and ovarian cancer was accepted by the FDA on March 27, 2025.
• The company underwent two reverse stock splits: 1-for-100 on January 8, 2025, and 1-for-20 on June 13, 2025.
• Approximately $4.2 million in net proceeds were raised from a public offering in February 2025.
• Approximately $4.2 million in net proceeds were received from ELOC fundings and Series A Preferred Warrants exercise during the nine months ended September 30, 2025.
• Approximately $2.6 million in net proceeds were received from Series D Preferred Stock sales during the nine months ended September 30, 2025.
• Approximately $2.25 million in gross proceeds were received from Series E Preferred Stock sales in October 2025.
• The issuance of shares under the Keystone Purchase Agreements could result in substantial dilution to existing stockholders.

Sentiment

Score: 3

Explanation: While there is positive clinical progress with CER-1236 receiving Orphan Drug and Fast Track designations and entering Phase 1 trials with no DLTs reported for initial patients, the company faces severe financial challenges including substantial net losses, a going concern warning, and a Nasdaq delisting. The significant dilution from preferred stock conversions and the need for substantial future financing create high uncertainty and risk for investors.

Positives

• CER-1236 received FDA Orphan Drug Designation for acute myeloid leukemia (AML) in July 2025.
• CER-1236 received FDA Fast Track Designation for AML in September 2025, which is designed to accelerate development and review.
• The Phase 1 clinical trial for CER-1236 in AML was initiated in May 2025, with four patients dosed and no dose-limiting toxicities observed in the first three patients.
• A second IND application for CER-T cell therapy in non-small cell lung cancer (NSCLC) and ovarian cancer was accepted by the FDA in March 2025.
• Preclinical studies demonstrated CER-1236 T cells' robust phagocytic and cytotoxic potency against various cancer cell lines (MCL, NSCLC, AML) and superior cross-presentation abilities.
• Preclinical safety/toxicology studies in mice showed no evidence of toxicity or on-target off-tumor responses for CER-1236.
• Successful capital raises include $4.2 million net from a February 2025 public offering, $4.2 million net from ELOC fundings and Series A Preferred Warrants exercise, $2.6 million net from Series D Preferred Stock sales, and $2.25 million gross from Series E Preferred Stock sales.

Negatives

• The company was delisted from Nasdaq to OTCQB as of October 31, 2025, due to non-compliance with listing standards, including stockholders' equity and bid price requirements.
• Reported a significant net loss of $15.4 million for the nine months ended September 30, 2025, an increase from $9.0 million in the prior year period.
• The accumulated deficit stands at $86.3 million as of September 30, 2025, indicating substantial historical losses.
• Current cash and cash equivalents of $1.9 million as of September 30, 2025, are insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• The potential resale of up to 729.6 million shares by Keystone Capital Partners, LLC, represents approximately 80.89% of fully-diluted outstanding common stock, posing a significant dilution risk and potential for stock price decline.
• Most outstanding common warrants are 'out-of-the-money,' making their exercise unlikely and limiting potential cash proceeds for the company.
• Material weaknesses in internal control over financial reporting were identified, leading to delayed SEC filings and potential future compliance issues.
• Large 'deemed dividends' of $24.96 million and $6.65 million were recorded for the nine months ended September 30, 2025, due to down-round triggering events on preferred stock conversions, indicating significant value transfer from common stockholders.
• A $500,000 write-off of deferred offering costs related to the Arena ELOC was recorded due to the unlikelihood of raising funds through that agreement.

Risks

• The substantial percentage of outstanding common stock offered for resale (approximately 80.89%) could cause the market price to decline significantly.
• Nasdaq delisting limits investors' ability to trade securities and subjects the company to additional trading restrictions, potentially reducing liquidity and market price.
• There is substantial doubt about the company's ability to continue as a going concern due to significant losses and insufficient funding.
• The business is highly dependent on the success of its lead product candidate, CER-1236; failure in clinical development or commercialization would be significantly harmful.
• Engineered CER-T cells represent a novel approach to cancer treatment, creating significant development and regulatory challenges.
• Current product candidates are in early clinical or preclinical development and may fail or suffer delays.
• Success in preclinical studies or early clinical trials may not be indicative of results in future clinical trials.
• Manufacturing genetically engineered products is complex, and difficulties could delay or prevent supply for clinical trials or commercialization.
• Inability to use CER-T cell technology in intended product candidates would materially limit revenue opportunities.
• Difficulty in identifying or discovering additional product candidates.
• Data from preclinical studies is limited and may change as patient data becomes available or may not be validated in future clinical trials.
• Clinical trials are difficult to design and implement, involve uncertain outcomes, and may not be successful.
• Dependence on patient enrollment in clinical trials; difficulties could delay or adversely affect clinical development activities.
• Intense competition from larger, better-funded pharmaceutical and biotechnology companies developing novel therapies and platform technologies.
• High dependence on key personnel; inability to attract and retain highly qualified personnel could hinder business strategy implementation.
• Need for substantial additional financing, which may be unobtainable or on acceptable terms, potentially leading to delays or termination of development.
• The issuance of shares upon conversion or exercise of outstanding preferred shares and warrants, and future financing transactions, may result in substantial dilution to stockholders.
• Compromised security measures or information technology systems could lead to material adverse impacts.
• Product candidates may cause undesirable side effects or have other properties that could halt clinical development, prevent regulatory approval, or limit commercial potential.
• Reliance on third parties to conduct clinical trials and manufacture supplies; failure to perform could delay or prevent regulatory approval or commercialization.
• Single supply relationships for certain key components pose risks of supply restriction, termination, or price increases.
• Reliance on specialty raw materials, which may not be available on acceptable terms or at all.
• Potential liability for damages from hazardous materials use or violations of environmental laws.
• The lengthy and expensive regulatory approval process has an uncertain outcome, and earlier study results may not be predictive.
• Changing regulatory requirements for cell therapy products could negatively impact the ability to complete clinical trials and commercialize products.
• Failure to obtain fast track, breakthrough therapy, or priority review designations, or if obtained, such designations may not lead to faster development or regulatory review/approval.
• The accelerated approval pathway may not lead to faster development or approval, and required post-approval studies may fail to verify clinical benefit.
• Orphan drug exclusivity may not be obtained or maintained, potentially allowing competing products to enter the market sooner.
• Stringent and changing privacy laws (e.g., GDPR, CCPA) and emerging AI regulations could lead to enforcement actions, litigation, fines, or business disruption.
• The impact of recent healthcare reform legislation and other changes in the healthcare industry and spending is unknown and may adversely affect the business model.
• Prior treatments can alter the cancer or target of CER-T cell therapy, negatively impacting chances for achieving clinical activity.
• Inability to protect intellectual property rights could reduce the value of products, services, and brand.
• Sales of a substantial number of securities in the public market by existing securityholders could cause the price of common stock and warrants to fall.
• Most outstanding common warrants are out-of-the-money, making their exercise unlikely and limiting potential proceeds.
• Identified material weaknesses in internal control over financial reporting; if remediation is ineffective, it could impair the ability to produce timely and accurate financial statements.
• Unstable market and economic conditions (e.g., interest rates, inflation, geopolitical turmoil, trade policies) may have serious adverse consequences on the business and stock price.
• Anti-takeover provisions in organizational documents and Delaware law could delay or prevent a change of control.
• Future acquisitions or strategic partnerships may increase capital requirements, dilute stockholders, or incur debt/contingent liabilities.
• Increased costs and demands upon management due to complying with laws and regulations affecting public companies.
• The company does not intend to pay dividends on its common stock, limiting returns to stock value appreciation.

Future Outlook

The company anticipates a significant increase in R&D expenses as it continues and expands preclinical and clinical development and manufacturing of its product candidates. Substantial additional financing will be required for commercial production and registrational trials. The company believes CER-1236 has the potential to address unmet medical needs and offer a differentiated therapeutic profile, and plans to expand its clinical development to solid tumors such as NSCLC and ovarian cancer, with a Phase 1 study expected to initiate in the first quarter of 2026.

Management Comments

• We believe CER-1236 will be active in both hematological malignancies and solid tumors.
• Our proprietary approach to T cell engineering is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
• Our intent is to become a leading biopharmaceutical company focused on the capital-efficient advancement of innovative anti-cancer product candidates targeting the unmet medical need associated with aggressive and difficult-to-treat hematological malignancies and solid tumors.
• We believe that the preferential attributes engineered into our CER-T cell therapies have the potential to represent a next-generation adoptive cellular immunotherapy approach and enable us to overcome many of the limitations which hinder the wider application of current CAR-T technology.
• We believe this novel mechanism of action will enable our advance of a single therapeutic construct to address the substantial unmet need for a safe and effective cell therapy offering an improved therapeutic profile, despite significant competition.

Industry Context

The company operates in the highly competitive and rapidly evolving cell and gene therapy sector, competing with numerous large pharmaceutical, biopharmaceutical, and biotechnology companies, as well as academic institutions. While CAR-T cell therapies have shown significant promise in hematological cancers, they face limitations in solid tumors and are associated with frequent severe side effects. The company's novel CER-T cell technology aims to overcome these limitations by integrating innate and adaptive immune responses and targeting TIM-4-L, which is broadly expressed on tumor cells but minimally on healthy cells. The regulatory landscape for cell therapies is dynamic, with the FDA establishing specialized offices and expedited review programs. Recent FDA investigations into T-cell malignancies linked to CAR-T therapies highlight ongoing safety scrutiny in the broader cell therapy field, which could impact public perception and regulatory requirements for all such treatments. The AML therapeutic market is projected to grow significantly, indicating a high unmet medical need that the company aims to address with CER-1236, as there are currently no approved cell therapeutic approaches for AML.

Comparison to Industry Standards

• Unlike currently approved CAR-T cell therapies (e.g., Gilead Sciences' Yescarta, Novartis' Kymriah, Bristol Myers Squibb's Breyanzi and Abecma, Janssen Biotech's Carvykti, Autolus Therapeutics' Aucatzyl) which are largely active in hematological B cell malignancies with cure rates not exceeding 60%, CER-1236 is designed to be active in both hematological malignancies and solid tumors.
• CER-1236 employs a novel targeting mechanism (TIM-4-L) and integrates both cytotoxic and phagocytic mechanisms, aiming to overcome limitations of conventional CAR-T technology, such as lack of specific tumor-associated antigens and limited proliferation in solid tumors.
• Preclinical studies demonstrated CER-1236 cells exhibit superior cross-presentation abilities compared to conventional T cells, potentially triggering a broader immune response.
• The company's CER-T cell manufacturing processes are designed to resemble those used for existing CAR-T cells, which could leverage well-defined regulatory guidelines and potentially shorten development timelines.
• Current AML treatment primarily involves decades-old combination chemotherapy (cytarabine and anthracycline) with varying response rates (70-80% for younger adults, 40-60% for older fit adults) and venetoclax-based therapies for older unfit adults (median survival ~14.7 months). There are no FDA-approved cell therapeutic approaches for AML, positioning CER-1236 to address a significant unmet medical need.

Management Changes

Corporate Governance

Legal Proceedings

• Nasdaq delisting proceedings due to non-compliance with listing rules, including the $2.5 million stockholders' equity requirement and the $1.00 minimum bid price requirement.
• An FDA clinical hold was placed on the Investigational New Drug (IND) application for CER-1236 in July 2024 due to insufficient nonclinical data, which was subsequently resolved in November 2024.

Related Party Transactions

• In February 2024, Series A Preferred Stock was issued to Daniel Corey ($150,000), Atwood-Edminster Trust dtd 4-2-2000 ($1,002,000), and Chris Ehrlich ($275,000) as part of the First PIPE Financing.
• Brian Atwood, a director, purchased 25,510 Pre-Funded Warrants and accompanying February 2025 Common Warrants for approximately $1 million in the February 2025 public offering.
• In April 2025, 6,250 shares of Series D Preferred Stock were issued in exchange for 1,000,279 shares of Stella Diagnostics, Inc. Series D Preferred Stock, a portion of which was owned by a related party investor who is a majority shareholder of Stella Diagnostics, Inc. and has representation on its board of directors.
• Consulting fees of $190,000 were incurred to members of the board of directors during the nine months ended September 30, 2025.
• Consulting fees of $75,000 were incurred to members of the board of directors during the period from February 14, 2024, to September 30, 2024.

Stakeholder Impact

• Shareholders face significant dilution risk from the potential resale of up to 729.6 million shares by Keystone Capital Partners, LLC, and from ongoing preferred stock conversions, which have already resulted in substantial 'deemed dividends.' The Nasdaq delisting to OTCQB will likely reduce liquidity and market visibility, negatively impacting share value.
• Employees may experience retention challenges due to the company's precarious financial condition and declining stock price, despite the use of equity-based compensation for motivation and retention.
• Future patients could benefit from the development of novel cancer treatments (CER-1236) for unmet medical needs in AML, NSCLC, and ovarian cancer, assuming successful clinical development and commercialization.
• Creditors face increased risk due to the company's 'going concern' warning, significant accumulated deficit, and ongoing need for additional financing.

Next Steps

• Initiate a Phase 1 study for CER-1236 in non-small cell lung cancer (NSCLC) and ovarian cancer in the first quarter of 2026.
• Treat the fifth patient in the Phase 1 AML clinical trial in February 2026.
• Continue ongoing and planned research and development activities for CER-T cell therapies and product candidates.
• Pursue preclinical studies and initiate clinical trials for other product candidates.
• Seek regulatory and marketing approvals for any product candidates that successfully complete clinical trials.
• Establish sales, marketing, and distribution infrastructure to commercialize any product candidate for which regulatory approval is obtained.
• Develop and refine the manufacturing process for product candidates.
• Obtain additional financing to fund operations and development activities.
• Remediate identified material weaknesses in internal control over financial reporting.
• Await the review decision from the Nasdaq Listing and Hearing Review Council regarding the delisting appeal.
• Explore listing alternatives for common stock, including OTC Markets.

Key Dates

Recommendation

The company is in a highly precarious financial position, marked by substantial and increasing net losses, an accumulated deficit of over $86 million, and a 'going concern' warning from its auditors. The recent delisting from Nasdaq to OTCQB is a severe blow to market liquidity and investor confidence. While there are positive clinical developments with CER-1236 receiving Orphan Drug and Fast Track designations and showing initial safety in Phase 1 trials, these early-stage successes are overshadowed by the company's critical need for significant additional financing, which will likely lead to further substantial dilution for common stockholders. The large 'deemed dividends' from preferred stock conversions already indicate significant value transfer away from common equity. Given the extreme financial risk, lack of a stable trading market, and the long, uncertain path to commercialization for its drug candidates, the stock represents a strong sell for any seasoned investor or institution.

Keywords

Immunotherapy, Cancer treatment, T cell therapeutics, CER-T cells, Acute Myeloid Leukemia (AML), FDA Fast Track Designation, FDA Orphan Drug Designation, Clinical trials, Biopharmaceutical, Nasdaq delisting, OTCQB, Equity Line of Credit, Dilution, Going Concern, Intellectual Property, Drug development, Oncology, TIM-4 ligand, CAR-T therapy, Preferred Stock, Warrants, Financial reporting, SEC filing, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer